VENT 01
Alternative Names: NLRP3 inhibitor - Ventus Therapeutics; VENT-01Latest Information Update: 14 May 2024
At a glance
- Originator Ventus Therapeutics
- Class Anti-inflammatories; Cardiovascular therapies; Hepatoprotectants; Small molecules; Urologics
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Preclinical Cardiovascular disorders; Kidney disorders; Liver disorders; Neurological disorders
- Research Autoimmune disorders; Inflammation